Key result
Vutrisiran consistently improves cardiovascular outcomes and mortality regardless of baseline tafamidis use.
Why the study?
Clinical evidence supporting the combined use of vutrisiran and tafamidis in transthyretin amyloidosis with cardiomyopathy is limited.
Does vutrisiran improve clinical outcomes in patients with transthyretin amyloidosis with cardiomyopathy regardless of baseline tafamidis use?
RCT
Stratified
Does vutrisiran improve clinical outcomes in patients with transthyretin amyloidosis with cardiomyopathy regardless of baseline tafamidis use?
Vutrisiran demonstrates consistent clinical benefits in ATTR-CM regardless of baseline tafamidis use, supporting its efficacy as both monotherapy and combination therapy.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“HELIOS-B remains the foundation of our approach to ATTR-CM, and the multiple presentations we're sharing this week reflect the continued depth of that program alongside the progress we're making in hypertension.”
Supports vutrisiran with or without tafamidis in ATTR-CM; extends HELIOS-B efficacy to combination regimens without interaction.
BACKGROUND: Vutrisiran, an RNA interference therapeutic that suppresses hepatic transthyretin production, improved survival and cardiovascular outcomes in transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy). Tafamidis, a transthyretin stabilizer, also improves clinical outcomes. Although combining these therapies is mechanistically appealing, clinical evidence supporting this approach is limited. OBJECTIVES: We sought to evaluate whether the treatment effects of vutrisiran differed according to baseline tafamidis use in HELIOS-B. METHODS: In HELIOS-B, patients with ATTR-CM were randomized to vutrisiran 25 mg or placebo every 3 months for up to 36 months, with tafamidis use permitted and stratified. We assessed treatment effects according to baseline tafamidis use for the primary outcome of all-cause mortality and recurrent cardiovascular events and secondary endpoints, including individual components of the primary outcome, composite of all-cause mortality, cardiovascular events and outpatient worsening heart failure events, functional capacity (6-minute walk distance), and health status (Kansas City Cardiomyopathy Questionnaire-overall summary score [KCCQ-OSS]). CONCLUSIONS: Treatment effect estimates for vutrisiran on clinical outcomes were consistent across baseline tafamidis strata, with no statistically significant interaction according to baseline tafamidis use, with reduced effect size noted in those receiving baseline stabilizers in comparison to monotherapy. These data underscore the need for future prospective studies examining combination therapy in this population. (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Hamatani et al. (2026) conducted an RCT in Transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran vs. Placebo was evaluated on All-cause mortality and recurrent cardiovascular events. Vutrisiran showed consistent treatment effects on clinical outcomes across baseline tafamidis strata with no significant interaction.
Synapse has enriched 10 related papers. Consider them for comparative context: